THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve- targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France. Details of the poster presentation ...

Core Viewpoint - Autonomix Medical, Inc. has received a new patent that enhances its catheter-based technology, indicating significant potential for application and expansion in treating diseases related to the nervous system [1][2]. Patent and Technology Development - The European Patent Office has granted Patent No. 3,226,792, which covers methods and systems for regulating organ and tumor growth, particularly in the field of neuromodulation [1]. - The company has a growing global patent portfolio with over 80 issued patents and 40 pending applications, showcasing its commitment to innovation [1][2]. Applications and Market Potential - The '792 patent includes methods to sense, ablate, and verify neurological traffic related to the prostate and lower urinary tract, potentially addressing conditions such as chronic prostatitis, hypogonadism, nocturia, and erectile dysfunction [3]. - The technology aims to target pain associated with pancreatic cancer by focusing on the celiac plexus, with plans to expand its applications to various peripheral nerve bundles [2][6]. Clinical Trials and Future Plans - The company is preparing to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 for the Autonomix Sensing and RF Ablation System, aimed at treating pancreatic cancer pain [4]. - The technology is positioned as a platform that could address multiple indications across a wide disease spectrum, including cardiology and chronic pain management [6]. Company Overview - Autonomix Medical, Inc. is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [5].

Core Viewpoint - Autonomix Medical, Inc. is preparing to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval of its innovative medical technology aimed at diagnosing and treating diseases of the nervous system [1][3]. Company Overview - Autonomix Medical, Inc. is focused on advancing technologies for the diagnosis and treatment of nervous system diseases, featuring a first-in-class platform system technology that includes a catheter-based microchip sensing array [4]. - The technology is designed to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4]. Clinical Development - The company is initially developing its technology for pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5]. Expert Engagement - Autonomix has engaged a team of U.S. and international medical experts in interventional radiology and cancer pain to guide its clinical and regulatory path, ensuring that pre-clinical and clinical studies align with the needs for the FDA De Novo submission expected in 2026 [1][2][3].

Core Insights - Autonomix Medical, Inc. announced that an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO) [1] Company Overview - Autonomix is a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies [4] - The initial development of this technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology has potential applications across various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Event Details - The poster presentation at ECIO 2025 is titled "Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study" [2] - The conference is recognized as a comprehensive platform for interventional oncology education, featuring over 140 lectures and 16 hands-on training sessions [2]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which may detect and differentiate neural signals with approximately 3,000 times greater sensitivity than current technologies [3] - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] Stock Option Grant - The Compensation Committee of Autonomix's Board of Directors approved an inducement stock option grant on March 17, 2025, for a new non-executive employee to purchase 7,500 shares of common stock [1] - The exercise price of the options is equal to the closing price of Autonomix's common stock on the grant date, and the options have a ten-year term, vesting in four equal annual installments [2]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][5] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Developments - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective approach to treating chronic pain and other conditions [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][2] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Development - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective treatment approach [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]

Core Insights - Autonomix Medical, Inc. has successfully completed the design lock for its Apex 6 Radiofrequency Generator, integrating enhancements into a fully integrated transvascular treatment platform named the Autonomix Sensing and RF Ablation System, which is on track for Investigational Device Exemption submission and potential U.S. clinical trial initiation in 2025 for pancreatic cancer pain [1][4] Group 1: Company Developments - The integration of the Apex 6 Generator into the Autonomix platform allows for a cost-effective and de-risked approach to accelerate development, following a transaction with RF Innovations, Inc. to license the intellectual property [2] - The company is collaborating with RF Innovations' manufacturing partner to facilitate equipment development, enhancing its manufacturing supply chain [3] Group 2: Market Need and Technology - There is a significant need to transform treatment for pancreatic cancer patients, focusing on effective pain relief and improved quality of life, with early clinical results indicating potential to address this unmet medical need [3] - The technology includes a catheter-based microchip sensing array capable of detecting neural signals with approximately 3,000 times greater sensitivity than current technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [5][6] Group 3: Future Plans - The company plans to submit an IDE and commence U.S. clinical trials in 2025 to support commercialization of the Autonomix Sensing and RF Ablation System for pancreatic cancer pain [4]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that detects neural signals with approximately 3,000 times greater sensitivity than current technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases [4] Technology Development - Initial development of the technology is targeted at pain treatment, specifically for pancreatic cancer, which causes severe pain and lacks reliable treatment options [5] - The technology has the potential to address various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Industry Engagement - Autonomix's abstract has been accepted for poster presentation at the 2025 Society of Interventional Radiology Annual Scientific Meeting, scheduled for March 29-April 2, 2025 [1][2] - The Society of Interventional Radiology represents over 8,000 professionals dedicated to improving patient care through image-guided therapies [2] - The annual meeting will focus on emerging methodologies, groundbreaking research, and networking opportunities within the interventional radiology field [2][3] Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation" will be delivered by Dr. Bela Kis on March 31, 2025, from 12:10 PM to 1:10 PM CT [9]

Core Insights - Autonomix Medical, Inc. is focused on innovative technologies for diagnosing and treating diseases of the nervous system [3][4] - The company will present at the LSI USA '25 Emerging Medtech Summit on March 18, 2025 [1][2] - Autonomix's technology includes a catheter-based microchip sensing array with approximately 3,000 times greater sensitivity than current technologies [3] Company Overview - Autonomix Medical, Inc. specializes in medical devices aimed at revolutionizing the diagnosis and treatment of nervous system diseases [3] - The company's platform technology is designed for transvascular diagnosis and treatment of peripheral nervous system diseases [3][4] - Initial development focuses on pain treatment, particularly for pancreatic cancer, which currently lacks reliable solutions [4] Technology and Applications - The technology is investigational and not yet cleared for marketing in the United States [4] - The platform has potential applications across various medical fields, including cardiology, hypertension, and chronic pain management [4]